PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
0.03
D/E ratio near Healthcare median of 0.03. Philip Fisher would examine if industry-standard leverage is optimal for the business model.
2.11
Concerning net debt at 1.25-1.5x Healthcare median of 1.41. Martin Whitman would look for hidden assets or restructuring potential.
-36.71
Negative coverage while Healthcare median is 0.00. Seth Klarman would scrutinize operating performance and look for turnaround catalysts.
2.36
Current ratio 75-90% of Healthcare median of 2.83. John Neff would demand higher margins to compensate for tighter liquidity.
No Data
No Data available this quarter, please select a different quarter.